Website of "Botulax" preparation"


  • Sustained therapeutic effect that lasts over time
  • Selective corrective effect, which determines the preservation of natural facial expressions against complete correction of facial wrinkles
  • Consistent toxicity from batch to batch of preparation production
  • Proven therapeutic equivalence with Botox* preparation
  • Excellent tolerance in patients
  • Worldwide recognition of the preparation, manufactured in 23 countries under various commercial names
  • The credibility and high production standards of the Korean pharmaceutical concern HUGEL Inc
Botulinum toxin of type A - hemagglutinin complex - is a highly purified neurotoxic protein produced in compliance with local and international GMP standards accepted throughout the world.
Dosage form: Lyophilisate for solution for intramuscular administration

Pharmacological group: muscle relaxant of peripheral action.
ATC code: М03АХ01


Temporary correction of the appearance of wrinkles in the upper third of the face (glabellar lines) in adults.

Main contraindications

  • A history of hypersensitivity to any component of the preparation;
  • inflammation at the site of the intended injection (s);
  • acute phase of infectious diseases;
  • myasthenia gravis or Lambert-Eaton syndrome;

Release form

50 U or 100 U of the preparation into a vial made of borosilicate glass type I (Eur. Pharm.) with a capacity of 5 ml, hermetically sealed with a rubber stopper and an aluminum cap with first opening control.
1 vial together with application instruction in a cardboard box.

Formula, per vial:
  • For dosage of 50 U:
    Active substance: botulinum toxin of type A - 50 U;
    Excipients: human serum albumin - 0.25 mg, sodium chloride - 0.45 mg.
  • For dosage of 100 U:
    Active substance: botulinum toxin of type A - 100 U;
    Excipients: human serum albumin - 0.5 mg, sodium chloride - 0.9 mg.

Storage conditions

At a temperature of 2 to 8 °C. Keep out of the reach of children. Expiry date: 3 years.

Legal classification

For use in specialized medical institutions.


Hugel Inc., Republic of Korea

Address for complaints

"ALLIANCE" LLC 115093, Russia, Moscow, 7 Pavlovskaya str.

**"Comparative randomized clinical study of the use of Botulax vs Botox for aesthetic correction of facial wrinkles." No. BOT-04-2011, 20.12.2013)

Please read the instructions for use

Informed voluntary consent to perform the procedure with Botulax preparation

Ask a question

* - mandatory fields

Added to cart
Fill in the contact details
and our manager will contact you:
Our manager will contact you soon.


Весь ассортимент в
одном приложении!